Krilogy Financial LLC Buys New Stake in STERIS plc $STE

Krilogy Financial LLC purchased a new position in STERIS plc (NYSE:STE) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 4,847 shares of the medical equipment provider’s stock, valued at approximately $1,179,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Stratos Wealth Partners LTD. increased its holdings in shares of STERIS by 4.0% in the third quarter. Stratos Wealth Partners LTD. now owns 18,030 shares of the medical equipment provider’s stock worth $4,461,000 after purchasing an additional 697 shares during the last quarter. Baader Bank Aktiengesellschaft grew its holdings in STERIS by 11.1% during the 3rd quarter. Baader Bank Aktiengesellschaft now owns 949 shares of the medical equipment provider’s stock valued at $235,000 after buying an additional 95 shares in the last quarter. Winslow Asset Management Inc. increased its stake in STERIS by 0.4% in the 3rd quarter. Winslow Asset Management Inc. now owns 32,309 shares of the medical equipment provider’s stock worth $7,995,000 after acquiring an additional 115 shares during the last quarter. Wealthfront Advisers LLC raised its holdings in shares of STERIS by 17.4% during the 3rd quarter. Wealthfront Advisers LLC now owns 5,580 shares of the medical equipment provider’s stock worth $1,381,000 after acquiring an additional 828 shares in the last quarter. Finally, ProShare Advisors LLC raised its holdings in shares of STERIS by 1.3% during the 3rd quarter. ProShare Advisors LLC now owns 23,348 shares of the medical equipment provider’s stock worth $5,777,000 after acquiring an additional 293 shares in the last quarter. Institutional investors own 94.69% of the company’s stock.

STERIS Trading Up 0.5%

Shares of STE stock opened at $244.58 on Friday. STERIS plc has a 1 year low of $204.90 and a 1 year high of $269.44. The company has a debt-to-equity ratio of 0.26, a current ratio of 2.48 and a quick ratio of 1.75. The stock’s 50 day simple moving average is $257.13 and its two-hundred day simple moving average is $250.20. The company has a market cap of $23.99 billion, a PE ratio of 34.11 and a beta of 1.03.

STERIS (NYSE:STE) last announced its earnings results on Wednesday, February 4th. The medical equipment provider reported $2.53 EPS for the quarter, hitting analysts’ consensus estimates of $2.53. STERIS had a return on equity of 14.34% and a net margin of 12.15%.The company’s revenue for the quarter was up 9.2% compared to the same quarter last year. During the same period in the previous year, the business posted $2.32 earnings per share. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. Research analysts predict that STERIS plc will post 9.08 earnings per share for the current year.

STERIS Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 19th. Shareholders of record on Tuesday, February 17th will be given a dividend of $0.63 per share. The ex-dividend date is Tuesday, February 17th. This represents a $2.52 dividend on an annualized basis and a yield of 1.0%. STERIS’s payout ratio is 35.15%.

Insider Buying and Selling at STERIS

In other news, VP Julia Madsen sold 5,008 shares of the firm’s stock in a transaction dated Friday, November 21st. The shares were sold at an average price of $262.00, for a total value of $1,312,096.00. Following the completion of the sale, the vice president owned 10,710 shares in the company, valued at approximately $2,806,020. This trade represents a 31.86% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Renato Tamaro sold 5,036 shares of STERIS stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $257.55, for a total transaction of $1,297,021.80. Following the transaction, the vice president directly owned 5,695 shares of the company’s stock, valued at approximately $1,466,747.25. This represents a 46.93% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 1.07% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “buy (b)” rating on shares of STERIS in a report on Friday, January 9th. Six investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $275.20.

About STERIS

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.